Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZBIO ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisOptions ChainTrends About ProShares UltraPro Short Nasdaq Biotechnology (NASDAQ:ZBIO) 30 days 90 days 365 days Advanced Chart Get ZBIO alerts:Sign Up Key Stats Today's Range$7.49▼$8.3050-Day Range$10.02▼$10.0952-Week Range$8.28▼$18.64Volume172,550 shsAverage Volume198,410 shsMarket Capitalization$327.22 millionAssets Under Management$2.85 millionDividend YieldN/ANet Expense Ratio0.95%Aggregate RatingN/A ETF OverviewZenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc?RIIb. Zenas BioPharma Inc. is based in WALTHAM, Mass.Read More… ProShares UltraPro Short Nasdaq Biotechnology ExpensesTypeZBIOHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.57%0.56%0.51%0.53%Other Expenses1.02%0.30%0.50%0.47%0.53%Total Expense1.77%0.70%0.72%0.67%0.71%Fee Waiver-0.82%-0.45%-0.50%-0.32%-0.56%Net Expense0.95%0.61%0.62%0.60%0.60% Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares UltraPro Short Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address ZBIO ETF News HeadlinesZenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune DiseasesFebruary 5, 2025 | globenewswire.comZenas BioPharma to Present at the Guggenheim SMID Cap Biotech ConferenceJanuary 28, 2025 | globenewswire.comDOGE To DO ListElon's found so much waste he's now claiming "the magnitude of the fraud in federal entitlements" is greater than "the combined sum of every private scam you've ever heard by FAR"... And while this is disturbing and even infuriating to see our tax money literally wasted... there IS a solution. I believe it's Elon's ultimate end game.February 24, 2025 | Altimetry (Ad)Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 12, 2024 | globenewswire.comZenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)November 12, 2024 | globenewswire.comZenas BioPharma to Participate in Upcoming Healthcare Investor ConferencesNovember 7, 2024 | globenewswire.comSee More Headlines ZBIO ETF - Frequently Asked Questions How were ProShares UltraPro Short Nasdaq Biotechnology's earnings last quarter? ProShares UltraPro Short Nasdaq Biotechnology (NASDAQ:ZBIO) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($5.02) earnings per share for the quarter, topping the consensus estimate of ($13.00) by $7.98. When did ProShares UltraPro Short Nasdaq Biotechnology IPO? ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) raised $225 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share. When does ProShares UltraPro Short Nasdaq Biotechnology's lock-up period expire? ProShares UltraPro Short Nasdaq Biotechnology's lock-up period expires on Wednesday, March 12th. ProShares UltraPro Short Nasdaq Biotechnology had issued 13,235,294 shares in its IPO on September 13th. The total size of the offering was $224,999,998 based on an initial share price of $17.00. After the end of ProShares UltraPro Short Nasdaq Biotechnology's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted. What other stocks do shareholders of ProShares UltraPro Short Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares UltraPro Short Nasdaq Biotechnology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI). Fund Details IssuerProShares Fund NameProShares UltraPro Short Nasdaq Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:ZBIO Inception Date6/22/2015 Fund ManagerMichael Neches, Tarak Dave Webwww.zenasbio.com Phone857-271-2954Fund Focus Asset ClassEquity BenchmarkNASDAQ Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings0 Fund Statistics Assets Under Management$2.85 million Average Daily Volume$25,501.70 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJPMorgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Miscellaneous Outstanding Shares41,790,000BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 2/24/2025 by MarketBeat.com Staff From Our PartnersMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryA little-known IRS loophole has been gaining serious attention... If you have a retirement account, you can...Premier Gold Co | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares UltraPro Short Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares UltraPro Short Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.